Drug Trial Radar · NCT03244384
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
739
Planned (sponsor's estimate)
Start
Nov 3, 2017
Primary completion
Jan 1, 2027
Study completion Jan 1, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Aug 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial studies how well pembrolizumab works in treating patients with bladder cancer that has spread into the deep muscle of the bladder wall (muscle-invasive) or urothelial cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Monoclonal antibodies recognizing and blocking checkpoint molecules can enhance the patient's immune response and therefore help fight cancer. Pembrolizumab is one of the monoclonal antibodies that block the PD-1 axis and can interfere with the ability of tumor cells to grow.
Conditions
- Localized Renal Pelvis and Ureter Urothelial Carcinoma
- Locally Advanced Bladder Urothelial Carcinoma
- Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma
- Locally Advanced Ureter Urothelial Carcinoma
- Locally Advanced Urothelial Carcinoma
- Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage II Renal Pelvis and Ureter Cancer AJCC v7
- Stage II Ureter Cancer AJCC v7
- Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage III Renal Pelvis and Ureter Cancer AJCC v7
- Stage III Ureter Cancer AJCC v7
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Clinical ObservationOther
Undergo observation
Computed TomographyProcedure
Undergo a CT scan
CT UrographyProcedure
Undergo a CT urography
CystoscopyProcedure
Undergo a cystoscopy
Magnetic Resonance ImagingProcedure
Undergo a MRI
PembrolizumabBiological
Given IV
Pharmacological StudyOther
Correlative studies
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: From randomization to the date of death from any cause, assessed up to 5 years
- Disease-free survivalTime frame: From randomization to the first metastatic recurrence (presence of any recurrent disease), or death, whichever occurs first, assessed up to 5 years
Locations
914 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Anchorage Radiation Therapy Center
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
CTCA at Western Regional Medical Center
Goodyear, Arizona
Kingman Regional Medical Center
Kingman, Arizona
Cancer Center at Saint Joseph's
Phoenix, Arizona
Mayo Clinic Hospital in Arizona
Phoenix, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona
Mercy Hospital Fort Smith
Fort Smith, Arkansas
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
John L McClellan Memorial Veterans Hospital
Little Rock, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California
PCR Oncology
Arroyo Grande, California
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Epic Care-Dublin
Dublin, California
Bay Area Breast Surgeons Inc
Emeryville, California
Epic Care Partners in Cancer Care
Emeryville, California
Kaiser Permanente-Fontana
Fontana, California
Kaiser Permanente South Bay
Harbor City, California
Kaiser Permanente-Irvine
Irvine, California
UC San Diego Moores Cancer Center
La Jolla, California
Loma Linda University Medical Center
Loma Linda, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Los Angeles General Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Kaiser Permanente West Los Angeles
Los Angeles, California
Contra Costa Regional Medical Center
Martinez, California
Fremont - Rideout Cancer Center
Marysville, California
Community Hospital of Monterey Peninsula
Monterey, California
Showing 40 of 914 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.